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ABSTRACT 
 
Despite the invaluable efficacy of statins, adherence to therapy is extremely poor in 
clinical practice. Improvement interventions should be as personalized as possible, but it 
is necessary to know factors that most influence adherence, and sex seems to be a key 
determinant. Thus, we aimed at exploring potential areas of sex-differences in statin 
adherence in a real-world population. For this purpose, we assessed adherence (as 
proportion of days covered) on a wide cohort of new statin users aged >40 years, and we 
evaluated its association with several covariates through sex-stratified log-binomial 
regression models. In addition, to compare also the benefits of optimal statin adherence 
in primary prevention of cardiovascular disease between men and women, we 
implemented sex-stratified Cox proportional hazard models. 
Our study showed that women are more likely to stop or be less adherent to statin 
treatment than men. Moreover, we observed significant sex-differences on effect size of 
several factors associated with adherence that should be taken into consideration for 
the management of patients. Finally, we observed no significant difference between 
men and women regarding statin efficacy in terms of reduction of incident 
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hospitalization for ischemic heart disease and/or non-haemorrhagic cerebrovascular 
disease. 
These results invoke the responsibility of physicians to a prompt and personalized 
intervention. Physicians should consider routine screening for non-adherence in their 
clinical practice, target patients at higher risk of non-adherence, and improved 
motivation and communication. 
 
Key Words: Statins; Adherence; Gender-medicine; Administrative database 
 
1. Background  
Statins are cholesterol-lowering drugs whose efficacy in reducing cardiovascular (CV) 
morbidity and mortality are one of the most remarkable successes of clinical CV 
medicine.[1-4] However, adherence to statin therapy is extremely poor in clinical 
practice.[5-8] Medication non-adherence usually refers to whether patients fail to take 
the medication as directed (dose and frequency of regimen) and/or discontinue it 
prematurely [9]. It is a growing concern to clinicians, healthcare systems, and other 
stakeholders,[10] because of its high prevalence and its association with adverse 
outcomes and higher costs of care.[11] 
Among the theories used to explore patient adherence to therapeutic regimens, one of 
the most commonly used is a patient-centred approach,[12, 13] in which the 
representations of illness (e.g., potential impact of the illness, symptoms experienced, 
illness controllability by treatment) made by patients guide their behaviour and 
performance with therapy. This approach can be strongly influenced by sex.[14] 
Although some evidence has suggested a gender difference in the extent of adherence to 
some chronic treatments, including the lipid-lowering therapy,[14] whether predictors 
of statin non-adherence may differ between sex has not been fully investigated.[14, 15] 
Furthermore, even if the association between good adherence to therapy and efficacy in 
terms of reduction of CV events is established,[16] whether the extent of this 
association is the same in men and women has been poorly addressed.[17] Thus, we 
aimed at exploring potential areas of sex-differences in statin adherence in the clinical 
practice, and at comparing the benefit gained by having an optimal statin adherence, in 
terms of hospitalization for ischemic heart disease and/or non-haemorrhagic 
cerebrovascular disease saved, between men and women. 
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2. Methods  
 
2.1. Data source and cohort selection 
This study used administrative databases of Lombardy region (data availability 2000-
2012), the most populated region in Italy (more than 10 million people, one-sixth of 
Italy's population). See Supplementary material for further details. 
The target population consisted of subjects with age >40 years, who have received a 
first prescription for statin medication (ATC C10AA) between January 1, 2002 and 
December 31, 2007. We defined the index date as the date of the first prescription fill 
for any statin in the study period. Patients were required to not have prior statin 
prescription in a two-year period before the index date, to select only incident users. 
Patients were also required to have 1 year of enrolment after the index date to allow 
complete adherence evaluation at 1-year of follow-up. 
 
2.2. Assessing adherence to statins 
Exposure to statins was inferred from the presence of prescriptions for any drugs 
belonging to the ATC class C10AA in the prescription database and was estimated by 
assuming a treatment schedule of one tablet per day. Adherence was measured through 
proportion of days covered (PDC), calculated as the ratio between the number of days 
covered by medication and the total number of days in follow-up. In the case of an early 
refill for the same drug (same statin at the same dosage), the start of this prescription 
was shifted after the end of the previous one. In the case of an early refill for a 
different dose or a different statin, this prescription was considered as a change in 
therapy and the previous one was truncated. See Supplementary material for detailed 
explanation. 
PDC ranges from 0 to 1, with 1 corresponding to 100% medication adherence. We defined 
a threshold for optimal adherence at 80% (PDC >0.80), which is a conventional threshold 
deemed necessary to obtain adequate therapeutic efficacy. [18] 
For the analysis of persistence, treatment discontinuation was defined as a gap of at 
least 30 days between the end of a prescription coverage and the beginning of the 
following one. As already reported in literature,[19-22] the gap was chosen to represent 
a period between doses that would lead to a decline in therapeutic effectiveness [23] 
and because it is the mean pharmaceutical dispensation duration for statin packages in 
Italy. A sensitivity analysis where treatment discontinuation was defined as a gap of at 
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least 60 days was also performed. The date of the end of the coverage of the last 
prescription before interruption was taken as the date of discontinuation. Persistence 
was defined as the lack of any discontinuation during follow-up. 
 
2.3. Covariates assessment 
A number of patient characteristics were captured from administrative databases and 
used as covariates. These characteristics were as follows: sex, age (at the time of the 
index date, divided into decades), comorbidity status based on Charlson Comorbidity 
Index (CCI, in a 2-year period before the index date),[24] hospitalization for hepatic 
(ICD-9 codes 570-573, V42.7) or renal disease (ICD-9 580-589, V42.0, V45.1), and 
hospitalization for CV events (ischemic heart disease [ICD-9 codes 410-414], non-
haemorrhagic cerebrovascular disease [ICD-9 codes 433-435, 437.0, 437.1]; all 
hospitalizations assessed in a 2-year period before the index date). The index statin was 
also classified as being high potency (rosuvastatin 10-20-40 mg, atorvastatin 20-40-80 
mg, simvastatin 40 mg) or medium/low potency (simvastatin 10-20 mg, pravastatin 20-
40 mg, lovastatin 20-40-80 mg, fluvastatin 40-80 mg, atorvastatin 10 mg, rosuvastatin 5 
mg).[25] The information on use of antidiabetic (ATC A10B), antihypertensive (ATC C02, 
C03, C07, C08, C09),antithrombotic (ATC B01A), and antidepressant (ATC N06A) 
treatments in a 2-year period before the index date were also retrieved, as well as the 
total number of drugs prescribed in 1-year period before the index date. 
 
2.4. Statistical Analysis 
Continuous variables were expressed as mean ± standard deviation (SD) and categorical 
data as number and percentage. Imbalances between sexes were assessed through 
standardized mean differences for binary, categorical and continuous covariates. 
Equipoise was considered to be reached when the between-group comparison of 
covariates above mentioned had an absolute value of <0.1.[26] 
Adherence was assessed at one year, i.e. all patients were followed-up for 365 days 
from the index date. Sex-stratified log-binomial regression models were fitted to 
estimate relative risks (RR) and 95% confidence intervals [95%CI] for the association 
between optimal adherence (PDC >0.80), and several covariates included age, number 
and type of co-medications at baseline, first statin potency, previous CV hospitalization, 
previous hospitalization for liver or kidney disease, and CCI (evaluated in the two years 
preceding the index date). 
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As secondary objective, we aimed at comparing the benefits of optimal statin adherence 
in primary prevention of cardiovascular disease (CVD) between men and women, two 
matched cohorts were defined as follows. After exclusion of patients with 
hospitalization for CV events before the index date and/or during the first year of 
follow-up, for each woman of the cohort, one man randomly selected from the same 
cohort was matched by age (±3) at cohort entry and 1-year PDC value (±0.10) as proxy of 
the patient’s attitude to the statin treatment in the first year of follow-up. The selected 
cohorts were then followed-up from the index date until the date of hospitalization for 
an ischemic heart disease and/or non-haemorrhagic cerebrovascular disease, end of 
membership in the database (i.e., emigration), end of database coverage (31/12/2012), 
or death, whichever occurred first. All statin prescriptions dispensed to the matched 
cohort members during this period of observation were identified. The adherence was 
assessed as PDC, and classified as low (≤0.40), intermediate (0.41 to 0.80), and high 
(>0.80) based on PDC values. Sex-stratified Cox proportional hazard models were fitted 
to estimate adjusted hazard ratios (HR) with corresponding 95%  confidence interval 
(95%CI) for hospitalization for CV events associated with statin adherence. Because drug 
exposure may vary over time, adherence categories were included in the model as time-
dependent variables, thereby accounting for their cumulative and varying nature.[27] 
Data processing was performed by SAS (Statistical Analysis System) software version 9.4 
(SAS. Institute, Inc. Cary, North Carolina), and two-tailed p<0.05 was considered for 
statistical significance in all analyses. 
 
3. Results 
 
3.1. Description of the cohort 
A total of 303,383 men and 310,271 women aged >40, incident users of statins in the 
period 2002-2007, were enrolled in the study. Baseline characteristics of selected cohort 
are shown in Table 1. Compared to women, men were younger (62.9±10.6 vs 65.7±10.8) 
but showed a higher prevalence of antithrombotic treatment (49.66% vs 37.55%), and of 
comorbidities (higher percentages for CCI equal to 1 and for CCI ≥2). Men also showed 
higher prevalence of hospitalization for CV events previous to the index date than 
women (24.25% vs 10.64%). Prescriptions of antidepressant drugs were more common 
among women than men (19.79% vs 10.57%). The percentage of subjects with at least 10 
prescribed drugs in the two years before the cohort entry was higher for women than 
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men (45.78% vs 35.76%). As first statin, simvastatin was the most frequently prescribed 
both for men and women (34.60% and 34.20%, respectively), followed by atorvastatin 
(32.76% and 30.50%, respectively); about 35% of men and 31% for women were firstly 
prescribed with a high potency statin. 
 
3.2. Adherence and persistence to statin therapy 
The average number of statin prescriptions filled in the first year of treatment was 
higher in men than in women (5.2±4.24 vs 4.5±4.0; Table 2). About 29% of men and 34% 
of women had only one statin prescription during the first year of follow-up. On average, 
the 1-year PDC was 0.48 (±0.35) for men and 0.41 (±0.32) for women; a similar 
difference was seen excluding patients with only one prescription (mean PDC 0.64±0.29 
and 0.57±0.28, respectively) but also selecting only men and women with a previous 
cardiovascular event (mean PDC 0.69±0.31 and 0.63±0.33, respectively). In men and 
women, the proportion of patients with a PDC >0.80 at 1-year was about 27% and 19%, 
respectively (Table 2). 
Evaluating adherence distribution according to age (Figure 1), average PDC was 
significantly higher for males in all age decades (p<0.001 for all decades) up to 81-90 
years, even if the differences between the two sexes become smaller as the age 
increases, becoming not significantly different for subjects over 90 years. Nevertheless, 
the proportion of subjects with PDC >0.80 was higher for males only up to the age of 70, 
since the proportion was later reversed in favour of the female sex.  
Sex-specific trends by months of the proportion of adherent patients are shown in 
Figure 2. For both sexes, the proportion of patients with optimal adherence sharply falls 
during the first five months (p<0.001), to 33% in men and to 25% in women. Afterwards, 
trends remained approximately stable afterwards, although still decreasing. Overall, 
men and women significantly differed for the trend in adherence (test for coincidence, 
p-value <0.001). The same analysis with the exclusion of subjects with only one 
prescription showed an overlapping trend, only settled at values on average 10 
percentage points higher for both women and men each month, up to 1-year proportion 
of adherent subjects equal to 28% in women and 38% in men. 
Regarding the analysis of persistence, 23.08% of male patients showed a continued use 
of medications, while the proportion was significantly lower in the female group 
(15.76%); on average, a continuous therapy lasted just under five months (136±136 days) 
and four months (121±124 days) for men and women, respectively (Table 2). The 
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percentage of persistent individuals was higher using a permissible gap of 60 days, but it 
was still significantly different between men and women (35.53% vs 27.14%, 
respectively). 
 
3.3. Factors associated with adherence to statin therapy 
The results of the application of the sex-stratified log-binomial regression models for the 
risk of optimal adherence (PDC >0.80) are reported in Figure 3. The model confirmed 
the role of age and concomitant medications as predictors of adherence. Compared to 
patients aged 51-60 years, younger and older (>70 years old) patients were less likely to 
be adherent to the statin treatment. Specifically, among subjects in the former class 
(41-50 years old), the likelihood of adherence was lower in women than men (tests of 
homogeneity for sex differences, p <0.0001). Also a past hospitalization for liver disease 
and receiving an antidepressant treatment before the index date were significantly 
associated with a low probability of optimal adherence for both sex, with a stronger and 
significant effect in women just in case of past hospitalization for liver disease (p 
<0.0001). Conversely, patients treated with high potency statins, or other cardiovascular 
drugs, with previous CV hospitalization, or more generally, with a severe health status 
based on CCI, were more likely to be adherent, with higher RR for men in case of high 
potency statins, presence of antihypertensive or antithrombotic treatment, and higher 
RR for women in case of antidiabetic treatment, and past hospitalization for CV events 
(all p <0.0001). Taking into account subjects with at least 10 prescribed drugs at 
baseline, we observed that women were more likely to be adherent to the statin 
treatment, while men with polypharmacy were at risk of not being adherent to the 
statin treatment, with a significant test of homogeneity for sex difference (p <0.0001). 
 
3.4. Statin adherence and incidence of hospitalization for CV events 
To evaluate the association between time-varying cumulative adherence and incidence 
of hospitalization for CV events, two matched cohorts of 175,069 men and 175,069 
women (ratio 1:1, with matching variables equally distributed among sexes) free from 
CVD at cohort entry was enrolled (baseline characteristics in Supplementary Table 1). 
Within this cohort, we identified 13,143 (7.51%) women and 24,923 (14.24%) men with a 
hospitalization for ischemic heart disease and/or non-haemorrhagic cerebrovascular 
disease during the follow-up. 
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As shown in Table 3, compared with women and men with a PDC ≤0.40, respectively, we 
found a significant risk reduction of hospitalisation for CV events with 0.41≤ PDC ≤0.80 
(HR 0.857 [0.826-0.890] for women and HR 0.891 [0.868-0.915] for men) and with PDC 
>0.80 (HR 0.812 [0.761-0.866] for women and HR 0.785 [0.751-0.820] for men). Tests of 
homogeneity for sex-differences did not show significant differences among these 
estimates. 
 
4. Discussion 
 
4.1. Principal findings 
This study explored sex-differences in adherence among new statin users in the primary 
care setting. Our results showed that (i) the rate of non-adherence is high in both sexes, 
(ii) women are more likely to stop or be less adherent to statin treatment than men, (iii) 
there are significant sex-differences on effect size of several factors associated with 
adherence, and (iv) the risk reduction of incident  hospitalization for CV events with 
increasing adherence shows no significant difference between men and women regarding 
statin efficacy. 
 
4.2. Sex and statin adherence 
The higher rate of non-adherence in women found in our cohort is in accordance with 
previous studies and consistent among different patient groups or different 
treatments.[28-30] In an observational study evaluating sex-differences in medication 
adherence of a large population of commercially insured US adults,[31] female patients 
were consistently less likely to be adherent with their diabetes medications, cholesterol 
medications, blood pressure medications, and antiplatelet medications compared with 
male patients, despite women tended to be more proactive in obtaining preventive care 
and treatment for medical conditions. In a retrospective cohort study of US adults who 
initiated statins in 2007–2014,[32] male sex was consistently shown to be associated with 
higher likelihood of high statin adherence and persistence. In a meta-analysis of 22 
cohort studies,[33] eighteen studies examined sex as a predictor of adherence, and the 
majority of these showed that women were less likely to be adherent to statins. Another 
meta-analysis of 53 studies [34] showed that compared with men, women had a 10% 
greater odds of non-adherence.  
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4.3. Sex-specific differences in the predictors of non-adherence 
The reasons for disparities between women and men in prescribed medications and 
adherence to them may relate to sex-specific factors.[14, 35] In general, from the 
patient’s perspective, issues such as satisfaction, health beliefs, naïve illness theories, 
and preferences for health care can all influence intentional non-adherence. Women 
may face different expectations and priorities that affect the attention they pay to 
maintaining their own health.[36] Moreover, men experienced less depression and 
anxiety and a more active problem-oriented and solving approach, all factors affect self-
care activity. Women instead, despite better knowledge of diseases, reported lower 
satisfaction with social support and lower quality of life.[37-40]  
Confirming that, our study has shown that some factors traditionally associated with 
higher or lower adherence to therapy have a different impact in the two sexes. 
We found a U-shape association between age and adherence for both sexes, an evidence 
already known from literature,[33] with younger and older subjects showing a lower 
adherence compared with individuals in the middle age. Prevalence of optimal 
adherence was significantly higher for males aged 41-70 years than for females of that 
age, but this relationship reversed later in life, though the mean PDC was higher for men 
in each age decade. The observation that younger people were less adherent than older 
individuals is consistent with the concept that people who perceive themselves to be at 
low risk for serious sequelae from hyperlipidaemia are more likely to be non-
adherent.[41, 42] This is probably more impactful for women, who have a better health 
condition and a lower prevalence of cardiovascular risk factors than men of the same 
age.[43, 44] Concerning elderly, the lower adherence pattern, confirmed by 
literature[45, 46], is probably consequent to comorbidities, polypharmacy, and cognitive 
dysfunction that commonly characterize this sub-sample of the population, and mainly 
the male population. With increasing age, and after menopause, women develop a 
greater awareness of their health status, especially if this becomes more severe, [43, 
47] and become more proactive and engaged in seeking, gaining and discussing health-
related issues,[48] which probably encourages them to be more compliant to treatment 
than men. Analogous considerations may explain the evidence that, compared with men, 
probability of optimal adherence was higher for women with previous CV hospitalization. 
Similarly, as the number of concomitantly administered drugs increases, the likelihood 
of being adherent increases in women, who are more likely to be adherent to the 
treatment if more than 10 drugs have been prescribed at the index date, while in men 
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more than 10 drugs prescribed at the index date significantly reduced the likelihood of 
optimal adherence. Also the presence of antidiabetic therapy increased the probability 
of optimal adherence more in women than in men (+29% in women vs +14% in men). As 
the prescriptions for these drugs are to be considered as a proxy not only for the 
pathological state, but also for the attempt to control disease through a specific 
therapy, this again could suggest that in women with a compromised clinical condition, 
efforts toward a proactive self-management are greater. Otherwise, the increase in the 
probability of optimal adherence with concomitant treatment with antihypertensive or 
antithrombotic drugs was more evident in men then in women; we can suppose that 
these therapies do not imply significant changes in lifestyle and self-management (as 
antidiabetic treatment), and they result in a higher adherence (especially in men) 
simply by favouring the ‘passive’ habit of taking a chronic therapy. 
Our study also found that men had a slightly higher probability to be adherent to statin 
treatment than women if they received a high-intensity statin as first statin prescribed 
(+22% vs +19%). The increase in adherence observed for both sexes with the use of high-
intensity statins may depend on the fact that the prescription reflects a more severe 
clinical condition. Nevertheless, the reason for a smaller RR in women could be that 
female patients experience more side effects from their medications.[49] Unpleasant 
side effects are a common reason for discontinuing medications, so higher rates of side 
effects in female patients [50] could contribute to lower rates of adherence.  
 
4.4. Sex difference in the association between statin adherence and hospitalization 
for CV events 
Whether statin therapy is as effective in women as in men is debated, especially for 
primary prevention.  The CTT Collaboration, in a meta-analysis using individual 
participant data from 174 000 participants in 27 randomised trials,[51] have been able to 
demonstrate conclusively that among women and men the effects of statin therapy on 
major vascular events and mortality were similar. This is true not only among high-risk 
populations with established CVD, but also when statin therapy was used for the primary 
prevention of CVD. In attempt to confirm whether women benefit to the same extent as 
do men from statin therapy for the primary prevention also in the primary care setting, 
we defined two matched cohorts of men and women without hospitalization for CV 
events before the index date. Our study detected an approximately 19% and 21% 
decrease in the risk of hospitalization for ischemic heart disease and/or non-
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haemorrhagic cerebrovascular disease among women and men with optimal adherence 
to statins (PDC >0.80) when they were compared with poor adherence subjects (PDC 
≤0.40), with no evidence of a sex-different efficacy of the statin treatment. The 
observation that the reduction of hospitalization for CV events is secondary to good 
adherence to statins regardless of the sex of the patient is confirmed by studies that 
failed to highlight differences between men and women in terms of statin 
efficacy/effectiveness.[52, 53] 
 
4.5. Impact on clinical practice 
The evidence of sex-based differences in factors influencing adherence can support 
improvement strategies, and in particular those that can be implemented by the doctor 
in a personalized way, for example through communication or practical approaches,[54, 
55] although the effectiveness of interventions aimed at improving adherence is still 
debated.[56] For example, our study showed that, compared to subjects aged 51-60 
years, younger patients have a lower probability of being adherent, especially if women. 
This suggests physician to pay a special attention to young female patients who are 
prescribed statins.  In this subgroup, it may be necessary to model communication 
processes, emphasizing the need for treatment and highlighting the risks associated with 
a lack of control of hypercholesterolemia. Still, the increased risk of non-adherence 
associated with hospitalizations for liver causes in the female population, perhaps 
indicating a greater fear of side effects associated with treatment in women, could 
suggest to the doctor who prescribes a statin to a woman to devote time in describing 
the risk-benefit profile of the drug, informing her of the true extent of the adverse 
effects and of their possible management. On the other hand, the concomitant poly-
therapy seems to negatively influence adherence only in the male population. In this 
case, the use of tools that help the patient to follow complex therapeutic regimes (such 
as pill boxes or written schemes indicating drugs, doses and timing of assumption) or 
solutions that simplify these regimes (such as the use of fix dose combinations when 
available) are to be preferred in male patients. 
 
4.6. Strengths and limitations 
Whilst administrative databases may constitute a fundamental source of readily 
available and relatively inexpensive large amounts of good quality data (demographic, 
clinical, economic) referring to the general population, the use of administrative 
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registry as data source may result in several limitations. First, adherence and 
persistence were derived from drug prescriptions: though widely used,[57] this method 
is based on several assumptions, such as the correspondence between prescription refill 
and medicine intake, and between the prescribed number of pills and days covered.[58] 
Nevertheless, the definition of the PDC index is likely to have allowed us to evaluate the 
prescriptive sequence with an approach closer to the real-life habit of patients. Second, 
we lack information regarding the reason for discontinuation of statin therapy, clinically 
appropriate in same cases.[59-61] Third, our data did not allow us to explore other 
potential predictors of non-adherence, such as cholesterol levels, life style habits (e.g. 
smoking), or socioeconomic factors (for example income, educational level, or marital 
status),[62] as these covariates are not recorded in administrative databases. Notably, 
among socioeconomic factors, the impact of income is probably smaller in the Italian 
context,[63] also because statin therapy is fully reimbursed by the National Health 
System.  
 
5. Conclusions 
Our findings support the need for physicians, pharmacists, and other health care 
professionals to address adherence in all patients taking statins, also considering that 
the association between optimal adherence and hospitalisation for CV events CV risk 
reduction was confirmed in both sexes. Moreover, the identification of sex-differences in 
the role of influencing factors confirms the existence of different mechanisms 
underlying the attitude of the two sexes towards pharmacological therapy, suggesting 
that greater benefits could be obtained by targeting male and female patients with a 
differentiated intervention, for example in men through a simplification of the 
therapeutic regimen and in women through a more emphatic communication.  
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Legends to the Figures 
 
Figure 1. Mean Daily Possession Ratio (PDC) and proportion of adherent patients (PDC >0.80) 
with statin medications at 1 year, according to sex and age decades.  
Student's t-test and Chi-square tests were used to compare mean PDC and proportion of adherent patients 
(PDC >0.80) by age decades between men and women. Significant differences are reported in the figure 
(*). 
The lines represent mean PDC values (y-axis on the left). The bars represent the proportion of patients 
with optimal adherence (PDC >0.80; y-axis on the right) 
 
Figure 2. Proportion of adherent patients with statin medications in the year after the 
beginning of the therapy according to sex. 
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Figure 3. Relative risk (RR) of optimal adherence levels (PDC >0.80) by sex. 
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Table 1. Characteristics of the patients who were newly treated with statin drugs during 2002-
2007 in the Lombardy Region (Italy) 
 Men N=303,383 
Women 
N=310,271 
Standardized 
differences 
Age (yy), mean±SD 62.9±10.6 65.7±10.8 0.263 
Age (yy), % 
41-50 14.34 8.80 
0.227 
51-60 26.69 23.39 
61-70 33.59 33.31 
71-80 21.05 26.02 
81-90 4.13 7.78 
>90 0.21 0.70 
Hospitalization for CV events, % 24.25 10.64 0.365 
Hospitalization for liver disease, % 1.40 0.83 0.054 
Hospitalization for kidney disease, % 2.28 1.22 0.081 
Prescribed drugs (N), 
% 
0-4 31.88 23.43 
0.292 5-9 32.36 30.79 
≥10 35.76 45.78 
Antidiabetic treatment, % 18.58 15.86 0.072 
Antihypertensive treatment, % 68.88 68.18 0.015 
Antithrombotic treatment, % 49.66 37.55 0.246 
Antidepressant treatment, % 10.57 19.79 0.259 
CCI, % 
0 71.78 83.80 
0.292 1 15.09 8.65 
≥2 13.13 7.55 
Statin, % 
Simvastatin 34.60 34.20 
0.133 
Lovastatin 1.55 1.79 
Pravastatin 12.47 13.16 
Fluvastatin 6.94 8.55 
Atorvastatin 32.76 30.50 
Rosuvastatin 11.79 11.80 
High potency statin, % 35.23 30.81 0.094 
*CV-Cardiovascular; CCI-Charlson Comorbidity Index; SD-standard deviation; yy-year 
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Table 2. Adherence and persistence to statin therapy during follow-up 
 Men N=303,383 
Women 
N=310,271 
Standardized 
differences 
Filled Prescriptions, N 1,568,612 1,406,560 
Number of prescriptions, mean±SD 5.2±4.24 4.5±4.0 0.244 
Patients with only one prescription, % 28.80 33.93 0.086 
Adherence    
PDC, mean±SD 0.48±0.35 0.41±0.32 0.209 
PDC >80%, % 27.08 18.77 0.199 
Persistence without gaps ≥30 days    
Persistent patients, % 23.08 15.76 0.186 
Days of continuous therapy, mean±SD 136.4±136.4 121.3±124.2 0.196 
Persistence without gaps ≥60 days    
Persistent patients, % 35.53 27.14 0.182 
Days of continuous therapy, mean±SD 181.9±148.1 155.5±141.7 0.182 
* PDC - proportion of days covered; SD-standard deviation 
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Table 3. Association between cumulative adherence to statin therapy and risk of 
hospitalization for ischemic heart disease and/or non-haemorrhagic cerebrovascular 
disease. Stratified analysis by sex. 
Sex    aHR* 95%CI
Men (N=175,069) 
PDC ≤0.40 1 Ref
0.41≤ PDC ≤0.80  0.891  0.868‐0.915 
PDC >0.80  0.785  0.751‐0.820 
Women (N=175,069) 
PDC ≤0.40  1  Ref 
0.41≤ PDC ≤0.80  0.857  0.826‐0.890 
PDC >0.80  0.812  0.761‐0.866 
*adjusted for statin potency, co-medications at baseline, previous hospitalization for liver or kidney 
disease, and CCI 
**PDC-proportion of days covered; aHR-adjusted hazard ratio; CI-confidence interval; Ref-reference 
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